Q3 2022 Results
Company overview
Financial review
2022 priorities
Appendix
References
Entresto® +31% cc, growing strongly across geographies
Sales evolution
USD m, % cc
US weekly TRX¹
Total prescriptions (000)
Ex-US
US
100
90
+31%
80
1,135
70
924
60
565
50
519
40
30
20
570
405
10
0
Q3 2021
Q3 2022
10/07/2015
прициу
23/09/2022
1 GROWTH
C
Entresto
AZ K &K L
Strong quarter performance
■ WW: Increased to >8m patients on treatment?
■
US: Accelerated momentum, ~1.1m TRx in Q3
Europe: Strong demand growth continues
Future growth drivers
☐
Only 1/3 of eligible HFrEF population on treatment in G72
Strong profile in clinical and RW settings in HF3,4
Guidelines (AHA/ACC/HFSA) support Entresto as
1st choice in HFrEF, expand support in HFPEF5,6
Hypertension: High unmet need in Asia Pacific
See last page for references TRX Total Prescriptions WW-Worldwide HFrEF - heart failure with reduced ejection fraction
HFSA Heart Failure Society of America HFPEF-heart failure with preserved ejection fraction
RW - Real world
AHA-American Heart Association ACC American College of Cardiology
8 Investor Relations | Q3 2022 Results
✓ NOVARTIS | Reimagining MedicineView entire presentation